Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluation correctly identifies rivaroxaban as XARELTO’s active ingredient and correctly notes that the supplied label section contains no information supporting the patent, exclusivity, or generic-entry claims.
Category Scores
Accurate Statements
Section 11 identifies rivaroxaban as the active ingredient in XARELTO.
Section 11 states that rivaroxaban is the active ingredient in XARELTO tablets and oral suspension.
The patent, exclusivity, and generic-entry claims are absent from the supplied label section.
Section 11 describes rivaroxaban and the XARELTO formulations but does not address patents, exclusivity, generic products, or market entry.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluation does not provide prescribing or use instructions, and its characterizations of what the supplied label does and does not say are accurate.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
No material improvement is needed for the label-based evaluation.